title: Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase type 3B.
abstract: Phosphodiesterases (PDEs) include a large group of structurally related enzymes that belong to at least seven related gene families (PDEs 1-7) that differ in their primary structure, affinity for cAMP and cGMP, response to specific effectors, sensitivity to specific inhibitors, and regulatory mechanism. One characteristic of PDE3s involves their phosphorylation and activation in response to insulin as well as to agents that increase cAMP in adipocytes, hepatocytes, and platelets and in response to insulin-like growth factor 1 in pancreatic beta cells. In adipocytes, activation of the membrane-associated PDE3B is the major mechanism whereby insulin antagonizes catecholamine-induced lipolysis. PDE3B activation results in increased degradation of cAMP and, thereby, a lowering of the activity of cAMP-dependent protein kinase (PKA). The reduced activity of PKA leads to a net dephosphorylation and decreased activity of hormone-sensitive lipase and reduced hydrolysis of triglycerides. Activation of the rat adipocyte PDE3B by insulin is associated with phosphorylation of serine-302. The mechanism whereby insulin stimulation leads to phosphorylation/activation of PDE3B is only partly understood. In rat adipocytes, lipolytic hormones and other agents that increase cAMP, including isoproterenol, also induce rapid phosphorylation, presumably catalyzed by PKA, of serine-302 of PDE3B. The phosphorylation is associated with activation of the enzyme, most likely representing "feedback" regulation of cAMP, presumably allowing close coupling of the regulation of steady-state concentrations of both cAMP and PKA and, thereby, control of lipolysis. In the review we describe methods and strategies used in the authors' laboratories to study phosphorylation and activation of PDE3B in adipocytes and in vitro.
authors.affiliation: Section for Molecular Signalling, Lund University, Lund, Sweden. Eva.Degerman@medkem.lu.se
authors.forename: E
authors.initials: E
authors.lastname: Degerman
authors.forename: T R
authors.initials: TR
authors.lastname: Landström
authors.forename: J
authors.initials: J
authors.lastname: Wijkander
authors.forename: L S
authors.initials: LS
authors.lastname: Holst
authors.forename: F
authors.initials: F
authors.lastname: Ahmad
authors.forename: P
authors.initials: P
authors.lastname: Belfrage
authors.forename: V
authors.initials: V
authors.lastname: Manganiello
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000502:physiology*; D017667:Adipocytes / Q000502:physiology*; D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D016384:Consensus Sequence / Q000235:genetics; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D004789:Enzyme Activation / Q000187:drug effects*; D006728:Hormones / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010748:Phosphopeptides / Q000032:analysis; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000502:physiology; D014357:Trypsin / Q000378:metabolism; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; D006728:Hormones; D007328:Insulin; D010726:Phosphodiesterase Inhibitors; D010748:Phosphopeptides; D011518:Proto-Oncogene Proteins; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D017868:Cyclic AMP-Dependent Protein Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; C517294:Pde3b protein, rat; D014357:Trypsin; D008666:Metalloendopeptidases; C058921:endoproteinase Asp-N; D007545:Isoproterenol; D000077191:Wortmannin